Apyx Lowers 2026 Expense Target, Keeps Revenue Outlook at $59 Million to $60 Million
Photo: TokenPost
Apyx Medical Corporation (NASDAQ: APYX) held its 2026 revenue forecast at $59 million to $60 million and lowered its operating expense target, narrowing the cost range while preserving its sales outlook. The company now expects full-year operating expenses of $41 million to $42.5 million, replacing its previous target of less than $45 million. Its revenue forecast includes $54 million to $55 million from Surgical Aesthetics and about $5 million from original-equipment-manufacturer sales. Apyx expects gross margins of 63% to 65%. The revenue outlook compares with $52.8 million in 2025. For the three months ended Sept.
Source: TokenPost
